FSIP2 and neoplasm: We divided our patients into two groups according to FSIP2 gene mutation and systematically compared tumor immunogenicity, the TME, expression of immune-related genes and signaling pathways between tumors with mutant FSIP2 (FSIP2-MT) or wild-type FSIP2 (FSIP2-WT), providing a theoretical basis for formulating new treatment options.